Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
249420.KS Stock Summary
In the News
249420.KS Financial details
Company Rating
Buy
Market Cap
471.22B
Income
-79.33B
Revenue
600.76B
Book val./share
6069.76
Cash/share
2909.85
Dividend
-
Dividend %
-
Employees
1.17K
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
-3.27
Forward P/E
9.87
PEG
0.95
P/S
0.76
P/B
3.36
P/C
5.41
P/FCF
-5.54
Quick Ratio
-
Current Ratio
0.68
Debt / Equity
1.19
LT Debt / Equity
0.09
-
-
EPS (TTM)
-2.96K
EPS next Y
1596
EPS next Q
-
EPS this Y
-35.37%
EPS next Y
-153.97%
EPS next 5Y
-153.97%
EPS last 5Y
38.88%
Revenue last 5Y
3.03%
Revenue Q/Q
1.04%
EPS Q/Q
-102.96%
-
-
-
-
SMA20
2.31%
SMA50
-1.86%
SMA100
-0.62%
Inst Own
-
Inst Trans
-
ROA
-23%
ROE
-82%
ROC
-0.31%
Gross Margin
36%
Oper. Margin
-12%
Profit Margin
-22%
Payout
-
Shs Outstand
27.93M
Shs Float
16.69M
-
-
-
-
Target Price
-
52W Range
14380.0-24450.0
52W High
-35.58%
52W Low
+9.53%
RSI
46
Rel Volume
1.39
Avg Volume
122.24K
Volume
170.46K
Perf Week
-1.62%
Perf Month
-3.49%
Perf Quarter
-24.64%
Perf Half Y
-24.1%
-
-
-
-
Beta
1.035
-
-
Volatility
401.33%, 326.35%
Prev Close
-1.87%
Price
15750
Change
-3.37%
249420.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 21.75K | 23.62K | 23.55K | 20.26K | 22.23K | |
Net income per share | -565.08 | -547.34 | -4.25K | -4.52K | -2.92K | |
Operating cash flow per share | 1.74K | 814.15 | -477.87 | -1.7K | -1.35K | |
Free cash flow per share | 925.25 | 6.74 | -1.31K | -2.32K | -2.03K | |
Cash per share | 3.81K | 3.62K | 6.5K | 2.5K | 3.01K | |
Book value per share | 10.63K | 10.7K | 6.43K | 6.08K | 6.27K | |
Tangible book value per share | 7.7K | 8.05K | 3.95K | 4.8K | 4.89K | |
Share holders equity per share | 10.63K | 10.7K | 6.43K | 6.08K | 6.27K | |
Interest debt per share | 7.19K | 7.21K | 9.95K | 6.91K | 7.99K | |
Market cap | 379.51B | 449.56B | 799.16B | 854.38B | 485.73B | |
Enterprise value | 455.48B | 530.85B | 889.73B | 1009.99B | 650.31B | |
P/E ratio | -28.23 | -34.53 | -7.91 | -6.01 | -6.15 | |
Price to sales ratio | 0.73 | 0.8 | 1.43 | 1.34 | 0.81 | |
POCF ratio | 9.17 | 23.21 | -70.31 | -15.96 | -13.27 | |
PFCF ratio | 17.24 | 2.81K | -25.65 | -11.68 | -8.86 | |
P/B Ratio | 1.5 | 1.77 | 5.23 | 4.47 | 2.86 | |
PTB ratio | 1.5 | 1.77 | 5.23 | 4.47 | 2.86 | |
EV to sales | 0.88 | 0.94 | 1.59 | 1.58 | 1.08 | |
Enterprise value over EBITDA | 17.08 | 14.86 | -37.67 | -23.19 | -25.91 | |
EV to operating cash flow | 11.01 | 27.41 | -78.28 | -18.86 | -17.76 | |
EV to free cash flow | 20.69 | 3.31K | -28.56 | -13.81 | -11.87 | |
Earnings yield | -0.04 | -0.03 | -0.13 | -0.17 | -0.16 | |
Free cash flow yield | 0.06 | 0 | -0.04 | -0.09 | -0.11 | |
Debt to equity | 0.66 | 0.66 | 1.48 | 1.09 | 1.19 | |
Debt to assets | 0.27 | 0.28 | 0.32 | 0.32 | 0.33 | |
Net debt to EBITDA | 2.85 | 2.28 | -3.83 | -3.57 | -6.56 | |
Current ratio | 1.1 | 1.26 | 0.83 | 0.89 | 0.75 | |
Interest coverage | -0.24 | 1.42 | -5.15 | -7.49 | -3.63 | |
Income quality | -3.08 | -1.49 | 0.11 | 0.38 | 0.46 | |
Dividend Yield | 0.02 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.64 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
Research and developement to revenue | 0.09 | 0.11 | 0.17 | 0.17 | 0.16 | |
Intangibles to total assets | 0.11 | 0.1 | 0.09 | 0.07 | 0.07 | |
Capex to operating cash flow | -0.47 | -0.99 | 1.74 | 0.37 | 0.5 | |
Capex to revenue | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | |
Capex to depreciation | -0.69 | -0.69 | -0.68 | -0.66 | -0.64 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 11.63K | 11.48K | 24.78K | 24.85K | 20.3K | |
ROIC | 0 | 0.02 | -0.09 | -0.19 | -0.12 | |
Return on tangible assets | -0.02 | -0.02 | -0.16 | -0.23 | -0.14 | |
Graham Net | -7.59K | -7.49K | -12.85K | -8.03K | -9.73K | |
Working capital | 21.52B | 48.23B | -62.59B | -34.26B | -78.55B | |
Tangible asset value | 183.28B | 191.48B | 93.96B | 151.1B | 132.15B | |
Net current asset value | -126.46B | -117.49B | -246.84B | -175.55B | -201.31B | |
Invested capital | 0.66 | 0.66 | 1.48 | 1.09 | 1.19 | |
Average receivables | 75.65B | 63.71B | 59.03B | 82.56B | 85.07B | |
Average payables | 30.17B | 37.88B | 37.16B | 42.22B | 48.17B | |
Average inventory | 61.47B | 79.49B | 85.91B | 90.42B | 91.44B | |
Days sales outstanding | 50.57 | 36.21 | 40.61 | 58.83 | 40.92 | |
Days payables outstanding | 50.91 | 40.61 | 41.07 | 41.92 | 46.64 | |
Days of inventory on hand | 89.29 | 100.69 | 88.48 | 89.35 | 78.55 | |
Receivables turnover | 7.22 | 10.08 | 8.99 | 6.2 | 8.92 | |
Payables turnover | 7.17 | 8.99 | 8.89 | 8.71 | 7.83 | |
Inventory turnover | 4.09 | 3.62 | 4.13 | 4.09 | 4.65 | |
ROE | -0.05 | -0.05 | -0.66 | -0.74 | -0.47 | |
Capex per share | -813.5 | -807.41 | -832.06 | -623.01 | -672.89 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 5.67K | 5.46K | 5.76K | 5.56K | 5.41K | |
Net income per share | -2.02K | -404.17 | -893 | -1.71K | 50.69 | |
Operating cash flow per share | -536.75 | -499.04 | -529.82 | -983.9 | 622.78 | |
Free cash flow per share | -759.01 | -643.27 | -702.58 | -1.24K | 519.49 | |
Cash per share | 2.94K | 2.29K | 2.03K | 2.36K | 2.91K | |
Book value per share | 7.14K | 6.73K | 5.83K | 4.88K | 6.07K | |
Tangible book value per share | 5.64K | 5.25K | 4.38K | 3.43K | 4.73K | |
Share holders equity per share | 7.14K | 6.73K | 5.83K | 4.88K | 6.07K | |
Interest debt per share | 7.86K | 7.77K | 8.42K | 1.56K | 7.3K | |
Market cap | 727.35B | 582.32B | 422.45B | 564.89B | 501.94B | |
Enterprise value | 882.95B | 745.31B | 605.94B | 568.63B | 666.53B | |
P/E ratio | -3.37 | -13.45 | -4.42 | -3.07 | 88.62 | |
Price to sales ratio | 4.79 | 3.99 | 2.74 | 3.78 | 3.32 | |
POCF ratio | -50.58 | -43.58 | -29.78 | -21.34 | 28.85 | |
PFCF ratio | -35.77 | -33.81 | -22.46 | -16.97 | 34.59 | |
P/B Ratio | 3.8 | 3.23 | 2.71 | 4.3 | 2.96 | |
PTB ratio | 3.8 | 3.23 | 2.71 | 4.3 | 2.96 | |
EV to sales | 5.81 | 5.1 | 3.93 | 3.8 | 4.41 | |
Enterprise value over EBITDA | -62.41 | 13.78 | 10.88 | 11.41 | 174.32 | |
EV to operating cash flow | -61.4 | -55.78 | -42.72 | -21.48 | 38.32 | |
EV to free cash flow | -43.42 | -43.28 | -32.22 | -17.08 | 45.93 | |
Earnings yield | -0.07 | -0.02 | -0.06 | -0.08 | 0 | |
Free cash flow yield | -0.03 | -0.03 | -0.04 | -0.06 | 0.03 | |
Debt to equity | 1.09 | 1.16 | 1.42 | 0.28 | 1.19 | |
Debt to assets | 0.32 | 0.32 | 0.35 | 0.06 | 0.33 | |
Net debt to EBITDA | -11 | 3.01 | 3.3 | 0.08 | 43.05 | |
Current ratio | 0.89 | 0.83 | 0.78 | 0.68 | 0.75 | |
Interest coverage | -7.9 | 22.9 | -5.62 | -3.07 | -1.07 | |
Income quality | 0.27 | 1.23 | 0.58 | 0.57 | 12.29 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | -0.01 | 0 | 0 | |
Sales general and administrative to revenue | 0.02 | 0.47 | 0.49 | 0.45 | 0.02 | |
Research and developement to revenue | 0.18 | 0.17 | 0.17 | 0.16 | 0.13 | |
Intangibles to total assets | 0.07 | 0.07 | 0.07 | 0.08 | 0.07 | |
Capex to operating cash flow | 0.41 | 0.29 | 0.33 | 0.26 | -0.17 | |
Capex to revenue | -0.04 | -0.03 | -0.03 | -0.05 | -0.02 | |
Capex to depreciation | -0.76 | -0.51 | -0.63 | -1 | -0.43 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 17.99K | 7.82K | 10.82K | 13.71K | 2.63K | |
ROIC | -0.07 | -0.03 | -0.05 | -0.08 | 0 | |
Return on tangible assets | -0.09 | -0.02 | -0.04 | -0.09 | 0 | |
Graham Net | -9.43K | -9.98K | -10.81K | -10.39K | -9.41K | |
Working capital | -34.26B | -54.86B | -77.9B | -110.98B | -78.55B | |
Tangible asset value | 151.1B | 140.44B | 117.14B | 92.28B | 132.15B | |
Net current asset value | -175.55B | -187.94B | -207.25B | -215.14B | -201.31B | |
Invested capital | 1.09 | 1.16 | 1.42 | 0.28 | 1.19 | |
Average receivables | 110.35B | 102.9B | 107.46B | 94.75B | 72.47B | |
Average payables | 48.17B | 49.71B | 49.98B | 42.72B | 44.52B | |
Average inventory | 98.97B | 102.36B | 107.28B | 98.9B | 87.17B | |
Days sales outstanding | 60.89 | 63.47 | 65.37 | 46.69 | 40.12 | |
Days payables outstanding | 42.85 | 52.19 | 42.67 | 35.02 | 46.06 | |
Days of inventory on hand | 91.32 | 104.21 | 98.85 | 80.99 | 77.56 | |
Receivables turnover | 1.48 | 1.42 | 1.38 | 1.93 | 2.24 | |
Payables turnover | 2.1 | 1.72 | 2.11 | 2.57 | 1.95 | |
Inventory turnover | 0.99 | 0.86 | 0.91 | 1.11 | 1.16 | |
ROE | -0.28 | -0.06 | -0.15 | -0.35 | 0.01 | |
Capex per share | -222.26 | -144.23 | -172.75 | -253.42 | -103.29 |
249420.KS Frequently Asked Questions
What is Ildong Pharmaceutical Co., Ltd. stock symbol ?
Ildong Pharmaceutical Co., Ltd. is a KR stock and trading under the symbol 249420.KS
What is Ildong Pharmaceutical Co., Ltd. stock quote today ?
Ildong Pharmaceutical Co., Ltd. stock price is $15750 today.
Is Ildong Pharmaceutical Co., Ltd. stock public?
Yes, Ildong Pharmaceutical Co., Ltd. is a publicly traded company.